The FDA's Phase 3-ready confirmation for GH001's CMC and device plans, combined with a strong cash position and newly granted U.S. patent, significantly de-risks the path to pivotal trial initiation. Traders should watch for the start of the global pivotal program in 2026 as the next major catalyst; any delay would be a negative signal.
Price Chart
Executive Summary
GH Research reported Q2 2026 financial results with a net loss of $15.1 million ($0.23 per share), widening from a $9.3 million loss ($0.15 per share) in Q2 2025, driven by increased R&D spending on the GH001 pivotal program. The company highlighted key regulatory progress, including FDA confirmation that its CMC and device plans appear Phase 3 ready, and the grant of a key U.S. patent for mebufotenin in MDD/TRD expiring in 2043. With $362.7 million in cash and marketable securities, the company is well-capitalized to initiate its global pivotal program for GH001 in TRD, targeted for later in 2026.
Key Facts
- Net loss for Q2 2026 was $15.1 million ($0.23 per share), compared to $9.3 million ($0.15 per share) in Q2 2025.
- Cash, cash equivalents and marketable securities totaled $362.7 million as of June 30, 2026, up from $280.7 million at year-end 2025.
- In July 2026, the FDA confirmed that the company's CMC and device plans for GH001 appear Phase 3 ready.
- The U.S. Patent and Trademark Office granted U.S. Patent No. 12,685,721 for methods of treating MDD and TRD with aerosolized mebufotenin, expiring no earlier than 2043.
- The European Patent No. 3 927 337 was maintained following an opposition hearing, covering mebufotenin for MDD and TRD via multiple routes, expiring no earlier than 2040.
- R&D expenses were $12.4 million in Q2 2026, up from $9.0 million in Q2 2025, driven by increased clinical development costs for GH001.
- The company completed an underwritten offering in April 2026, raising net proceeds of $111.2 million.
- GH001 Phase 2b data showed a 57.5% Day 8 remission rate and 73% remission at 6 months in OLE completers.
Financial Impact
Net loss widened by $5.9 million YoY to $15.1 million in Q2 2026, with R&D spend increasing $3.4 million to $12.4 million. Cash position strengthened by $82.0 million to $362.7 million following a $111.2 million net equity offering.
Risk Factors
- Clinical trial failure or delay in the GH001 pivotal program.
- Regulatory setbacks, including potential FDA clinical hold or unfavorable guidance.
- Dilution risk from the $200 million ATM program established in May 2026, though no shares have been sold to date.
- Competitive pressure from other psychedelic and rapid-acting antidepressant developers (e.g., Spravato, BPL-003, VLS-01, COMP360).
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 8 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 6-K Filing (Primary) | 0001140361-26-031506 |
| Document: ef20075260_ex99-2.htm | 0001140361-26-031506 |
| Document: ef20075260_ex99-3.htm | 0001140361-26-031506 |
| Document: ef20075260_6k.htm | 0001140361-26-031506 |
| Document: ef20075260_ex99-4.htm | 0001140361-26-031506 |
| Document: 0001140361-26-031506-index-headers.html | 0001140361-26-031506 |
| Document: 0001140361-26-031506-index.html | 0001140361-26-031506 |
| Document: 0001140361-26-031506.txt | 0001140361-26-031506 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 9, 2026 18d ago | 6-K | $21.11 $18.15 | ▼ −14.02% | ▼ −12.05% | $20.01 (−5.21%) |
Sep 11, 2026 6w ago | 6-K | $27.20 $28.26 | ▲ +3.90% | ▲ +4.12% | $20.01 (−26.43%) |
Aug 6, 2026 11w ago | 6-K | $30.64 $28.19 | ▼ −8.00% | ▼ −9.21% | $20.01 (−34.69%) |
May 14, 2026 23w ago | 424B5 | $22.21 $21.77 | ▲ +1.98% | ▲ +1.26% | $20.01 (+9.91%) |
May 14, 2026 23w ago | 6-K | $22.21 $21.77 | ▼ −1.98% | ▼ −1.26% | $20.01 (−9.91%) |
May 14, 2026 23w ago | Press Release | $22.21 $21.77 | ▼ −1.98% | ▼ −1.26% | $20.01 (−9.91%) |
May 13, 2026 23w ago | 6-K | $22.21 $21.77 | ▲ +1.98% | ▲ +1.26% | $20.01 (+9.91%) |
Apr 29, 2026 25w ago | 424B5 | $19.16 $21.28 | ▼ −11.06% | ▼ −7.95% | $20.01 (−4.44%) |
Apr 1, 2026 29w ago | 3 | $14.57 $15.72 | ▲ +7.89% | ▲ +4.27% | $20.01 (+37.34%) |
Mar 25, 2026 30w ago | Press Release | $13.65 $14.72 | ▲ +7.84% | ▲ +8.08% | $20.01 (+46.59%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers